MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA.

Abstract:

BACKGROUND:We previously described a t(2;11)(p21;q23) chromosomal translocation found in patients with myelodysplasia or acute myeloid leukemia that leads to over-expression of the microRNA miR-125b, and we showed that transplantation of mice with murine stem/progenitor cells overexpressing miR-125b is able to induce leukemia. In this study, we investigated the mechanism of myeloid transformation by miR-125b. DESIGN AND METHODS:To investigate the consequences of miR-125b over-expression on myeloid differentiation, apoptosis and proliferation, we used the NB4 and HL60 human promyelocytic cell lines and the 32Dclone3 murine promyelocytic cell line. To test whether miR-125b is able to transform myeloid cells, we used the non-tumorigenic and interleukin-3-dependent 32Dclone3 cell line over-expressing miR-125b, in xenograft experiments in nude mice and in conditions of interleukin-3 deprivation. To identify new miR-125b targets, we compared, by RNA-sequencing, the transcriptome of cell lines that do or do not over-express miR-125b. RESULTS:We showed that miR-125b over-expression blocks apoptosis and myeloid differentiation and enhances proliferation in both species. More importantly, we demonstrated that miR-125b is able to transform the 32Dclone3 cell line by conferring growth independence from interleukin-3; xenograft experiments showed that these cells form tumors in nude mice. Using RNA-sequencing and quantitative real-time polymerase chain reaction experiments, we identified multiple miR-125b targets. We demonstrated that ABTB1, an anti-proliferative factor, is a new direct target of miR-125b and we confirmed that CBFB, a transcription factor involved in hematopoiesis, is also targeted by miR-125b. MiR-125b controls apoptosis by down-regulating genes involved in the p53 pathway including BAK1 and TP53INP1. CONCLUSIONS:This study demonstrates that in a myeloid context, miR-125b is an oncomiR able to transform cell lines. miR-125b blocks myeloid differentiation in part by targeting CBFB, blocks apoptosis through down-regulation of multiple genes involved in the p53 pathway, and confers a proliferative advantage to human and mouse myeloid cell lines in part by targeting ABTB1.

journal_name

Haematologica

journal_title

Haematologica

authors

Bousquet M,Nguyen D,Chen C,Shields L,Lodish HF

doi

10.3324/haematol.2011.061515

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

1713-21

issue

11

eissn

0390-6078

issn

1592-8721

pii

haematol.2011.061515

journal_volume

97

pub_type

杂志文章
  • Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report.

    abstract::Asparaginase-associated pancreatitis is a life-threatening toxicity to childhood acute lymphoblastic leukemia treatment. To elucidate genetic predisposition and asparaginase-associated pancreatitis pathogenesis, ten trial groups contributed remission samples from patients aged 1.0-17.9 years treated for acute lymphobl...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.199356

    authors: Wolthers BO,Frandsen TL,Patel CJ,Abaji R,Attarbaschi A,Barzilai S,Colombini A,Escherich G,Grosjean M,Krajinovic M,Larsen E,Liang DC,Möricke A,Rasmussen KK,Samarasinghe S,Silverman LB,van der Sluis IM,Stanulla M,Tulstr

    更新日期:2019-03-01 00:00:00

  • Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid.

    abstract::n patients with Kasabach-Merritt syndrome (KMS), local activation of coagulation commonly results in disseminated intravascular coagulation (DIC). Progress of DIC is associated with 30-40% mortality as a result of uncontrollable hemorrhage. A 39-year-old woman with an enlarging giant liver hemangioma was diagnosed as ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Ontachi Y,Asakura H,Omote M,Yoshida T,Matsui O,Nakao S

    更新日期:2005-11-01 00:00:00

  • Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

    abstract::This phase Ib/II trial combined the pan-deacetylase inhibitor panobinostat with chemotherapy followed by panobinostat maintenance in elderly patients with newly diagnosed acute myeloid leukemia. Patients with prior history of myelodysplastic syndrome were excluded and 38 evaluable patients were included in the study (...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2015.129577

    authors: Ocio EM,Herrera P,Olave MT,Castro N,Pérez-Simón JA,Brunet S,Oriol A,Mateo M,Sanz MÁ,López J,Montesinos P,Chillón MC,Prieto-Conde MI,Díez-Campelo M,González M,Vidriales MB,Mateos MV,San Miguel JF,PETHEMA Group.

    更新日期:2015-10-01 00:00:00

  • Genetic modifiers of beta-thalassemia.

    abstract::As the defective genes for more and more genetic disorders become unravelled, it is clear that patients with apparently identical genotypes can have many different clinical conditions even in simple monogenic disorders. Beta thalassemia occurs when there is a deficiency in the synthesis of beta globin chains. The clin...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Thein SL

    更新日期:2005-05-01 00:00:00

  • Corticosteroids can reverse severe imatinib-induced hepatotoxicity.

    abstract:BACKGROUND:Imatinib can induce severe hepatotoxicity, in 1-5% of CML patients, many of whom need permanent imatinib discontinuation. DESIGN AND RESULTS:We report 5 CML patients who developed grade 3-4 hepatotoxicity after 2-8 months in imatinib. Different aetiologies of liver damage were ruled out and toxicity recurre...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Ferrero D,Pogliani EM,Rege-Cambrin G,Fava C,Mattioli G,Dellacasa C,Campa E,Perfetti P,Fumagalli M,Boccadoro M

    更新日期:2006-06-01 00:00:00

  • Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-κB pathway.

    abstract::Chronic lymphocytic leukemia (CLL) is a disease with heterogeneous clinical and biological characteristics. Differences in Ca2+ levels among cases, both basal and upon B-cell receptor (BCR) stimulation, may reflect heterogeneity in the pathogenesis due to cell-intrinsic factors. Our aim was to elucidate cell-intrinsic...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.215566

    authors: Meijers RWJ,Muggen AF,Leon LG,de Bie M,van Dongen JJM,Hendriks RW,Langerak AW

    更新日期:2020-01-01 00:00:00

  • CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.

    abstract::CLLU1, located at chromosome 12q22, encodes a transcript specific to chronic lymphocytic leukemia and has potential prognostic value. We assessed the value of CLLU1 expression in the LRF CLL4 randomized trial. Samples from 515 patients with chronic lymphocytic leukemia were collected immediately before the start of tr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.070201

    authors: Gonzalez D,Else M,Wren D,Usai M,Buhl AM,Parker A,Oscier D,Morgan G,Catovsky D

    更新日期:2013-02-01 00:00:00

  • A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

    abstract::Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared with placebo (COMFORT-I) and best available therapy (COMFORT-II). We pre...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3324/haematol.2014.119545

    authors: Vannucchi AM,Kantarjian HM,Kiladjian JJ,Gotlib J,Cervantes F,Mesa RA,Sarlis NJ,Peng W,Sandor V,Gopalakrishna P,Hmissi A,Stalbovskaya V,Gupta V,Harrison C,Verstovsek S,COMFORT Investigators.

    更新日期:2015-09-01 00:00:00

  • Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases.

    abstract:BACKGROUND AND OBJECTIVES:The available data on the immunoglobulin gene (IG) repertoire in multiple myeloma (MM) derive mainly from heavy chains; considerably less is known about light chains. We assessed in parallel IGH and IGK/IGL rearrangements in 101 MM patients so as to gain insight into: (i) IG repertoires; (ii) ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Hadzidimitriou A,Stamatopoulos K,Belessi C,Lalayianni C,Stavroyianni N,Smilevska T,Hatzi K,Laoutaris N,Anagnostopoulos A,Kollia P,Fassas A

    更新日期:2006-06-01 00:00:00

  • Primary lymphoma of the vagina. A case report.

    abstract::Primary vaginal non-Hodgkin lymphoma is really uncommon and may be misdiagnosed as inflammatory disease or solid cancer, so careful diagnostic procedures are needed, particularly as far as pathological and immunocytochemical evaluation is concerned. Most of these lymphomas present with follicular patterns and limited ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Lonardi F,Ferrari V,Pavanato G,Bonciarelli G,Jirillo A,Balli M

    更新日期:1994-03-01 00:00:00

  • Fit αβ T-cell receptor suppresses leukemogenesis of Pten-deficient thymocytes.

    abstract::Signaling through the αβT cell receptor (TCR) is a crucial determinant of T-cell fate and can induce two opposite outcomes during thymocyte development: cell death or survival and differentiation. To date, the role played by T-cell receptor in the oncogenic transformation of developing T cells remains unclear. Here we...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.188359

    authors: Gon S,Loosveld M,Crouzet T,Potier D,Bonnet M,Morin SO,Michel G,Vey N,Nunès JA,Malissen B,Roncagalli R,Nadel B,Payet-Bornet D

    更新日期:2018-06-01 00:00:00

  • Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies.

    abstract::The aim of this study was to investigate the microRNA (miRNA) expression pattern in neutrophils from rheumatoid arthritis (RA) patients and its contribution to their pathogenic profile and to analyze the effect of specific autoantibodies or inflammatory components in the regulation of miRNA in RA neutrophils and its m...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.205047

    authors: De la Rosa IA,Perez-Sanchez C,Ruiz-Limon P,Patiño-Trives A,Torres-Granados C,Jimenez-Gomez Y,Del Carmen Abalos-Aguilera M,Cecchi I,Ortega R,Caracuel MA,Calvo-Gutierrez J,Escudero-Contreras A,Collantes-Estevez E,Lopez-Pedrera C

    更新日期:2020-09-01 00:00:00

  • Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.

    abstract:BACKGROUND:An effective second-line treatment for intermediate and high grade non-Hodgkin's lymphoma is greatly needed since 30% of patients do not achieved complete remission (CR) and another 20% to 30% of the CRs will eventually relapse. METHODS:A four-drug combination with Mitoxantrone, Etoposide, Cisplatin and Dex...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Vitolo U,Orsucci L,Bertini M,Cavallero G,Gallamini A,Ghio R,Levis A,Rota-Scalabrini D,Resegotti L

    更新日期:1991-01-01 00:00:00

  • 1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis.

    abstract::The effect of treatment with 1,25-dihydroxyvitamin D3 administered at the dose of 1.50-3.00 ug/day for at least 12 months was evaluated in three patients with idiopathic myelofibrosis and in five patients with idiopathic thrombocythemia. This treatment did not cause any significant change in the hematological values o...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Foa P,Maiolo AT,Cortellaro M,Ortolani S,Pogliani E,Deliliers GL,Iurlo A,Zocchi L,Gualdoni A,Polli E

    更新日期:1990-05-01 00:00:00

  • Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433.

    abstract::Outcomes after relapse of childhood B-acute lymphoblastic leukemia (B-ALL) are poor, and optimal therapy is unclear. Children's Oncology Group study AALL0433 evaluated a new platform for relapsed ALL. Between March 2007 and October 2013 AALL0433 enrolled 275 participants with late bone marrow or very early isolated ce...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.237230

    authors: Lew G,Chen Y,Lu X,Rheingold SR,Whitlock JA,Devidas M,Hastings CA,Winick NJ,Carroll WL,Wood BL,Borowitz MJ,Pulsipher MA,Hunger SP

    更新日期:2021-01-01 00:00:00

  • Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography.

    abstract::The present study reports a method for the easy, rapid and cost effective detection of heterozygous large deletions. As a model gene all exons of the antithrombin gene were amplified in a one tube multiplex polymerase chain reaction (PCR) and the products separated according to their size by reverse-phase ion-pair hig...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Pavlova A,El-Maarri O,Luxembourg B,Lindhoff-Last E,Kochhan L,Bruhn HD,Delev D,Watzka M,Seifried E,Oldenburg J

    更新日期:2006-09-01 00:00:00

  • T-cell receptor repertoire usage after allografting differs between CD4+CD25+ regulatory T cells and their CD4+CD25- counterpart.

    abstract:BACKGROUND AND OBJECTIVES:After allogeneic haematopoietic stem cell transplantation (SCT) the whole T-cell receptor (TCR) repertoire shows a markedly skewed pattern for 2-3 years. A small fraction of CD4+ T cells is represented by CD25+ regulatory lymphocytes (Treg), which play a crucial role in modulating peripheral t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.10774

    authors: Fozza C,Nadal E,Longinotti M,Dazzi F

    更新日期:2007-02-01 00:00:00

  • Hb Foggia or alpha 117(GH5)Phe -> Ser: a new alpha 2 globin allele affecting the alpha Hb-AHSP interaction.

    abstract::We report a novel alpha2-globin gene allele with the mutation cod 117 TTC>TCC or alpha 117(GH5)Phe>Ser detected in three carriers with alpha-thalassemia phenotype. The mutated mRNA was present in the reticulocytes in the same amount as the normal one, but no chain or hemoglobin variant were detected. Most likely the a...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.11789

    authors: Lacerra G,Scarano C,Musollino G,Flagiello A,Pucci P,Carestia C

    更新日期:2008-01-01 00:00:00

  • CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

    abstract::Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are their low efficacy in eradicating the leukemic stem cells responsible for disease maintenance and relapse upon drug cessation. Herein, we p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2017.169946

    authors: Landberg N,von Palffy S,Askmyr M,Lilljebjörn H,Sandén C,Rissler M,Mustjoki S,Hjorth-Hansen H,Richter J,Ågerstam H,Järås M,Fioretos T

    更新日期:2018-03-01 00:00:00

  • Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.

    abstract:BACKGROUND:The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis - acute myeloid leukemia with myelodysplasia-related changes (≥20% myeloblasts of all nucleated c...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.043687

    authors: Bacher U,Haferlach C,Alpermann T,Kern W,Schnittger S,Haferlach T

    更新日期:2011-09-01 00:00:00

  • Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European

    abstract::Aplastic anemia is usually treated with immunosuppression or allogeneic transplant, depending on patient and disease characteristics. Syngeneic transplant offers a rare treatment opportunity with minimal transplant-related mortality, and offers an insight into disease mechanisms. We present here a retrospective analys...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.091074

    authors: Gerull S,Stern M,Apperley J,Beelen D,Brinch L,Bunjes D,Butler A,Ganser A,Ghavamzadeh A,Koh MB,Komarnicki M,Kröger N,Maertens J,Maschan A,Peters C,Rovira M,Sengeløv H,Socié G,Tischer J,Oneto R,Passweg J,Marsh J

    更新日期:2013-11-01 00:00:00

  • Migfilin supports hemostasis and thrombosis through regulating platelet αIIbβ3 outside-in signaling.

    abstract::Elucidating the regulation mechanism of integrin αIIbβ3 is key to understand platelet biology and thrombotic diseases. Previous in vitro studies have implicated a role of migfilin in the support of platelet αIIbβ3 activation, however, contribution of migfilin to thrombosis and hemostasis in vivo and a detailed mechani...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.232488

    authors: Zhou Y,Hu M,Chen X,Wang S,Li J,Sa L,Li L,Huang J,Cheng H,Hu H

    更新日期:2020-11-01 00:00:00

  • Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.

    abstract:BACKGROUND AND OBJECTIVE:The use of intensive therapy supported by autologous stem cell transplantation (ASCT) is being investigated as treatment for poor-prognosis follicular lymphomas (FL). A single-center experience is herein reported. DESIGN AND METHODS:From September 1990 to October 1997, 30 consecutive patients ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: López R,Martino R,Sureda A,Nomdedéu J,Briones J,Martin-Henao G,García J,Brunet S,Sierra J

    更新日期:1999-04-01 00:00:00

  • Cytokines in combination to treat radiation-induced myelosuppresssion: evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys.

    abstract::Multicytokine therapy may be useful to counteract radiation-induced myelosuppression. We assessed the stem cell factor + glycosylated erythropoietin + pegylated granulocyte colony-stimulating factor combination (SEG) as an emergency treatment. SEG in highly irradiated monkeys efficacy appeared to be restricted to gran...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.12183

    authors: Drouet M,Delaunay C,Grenier N,Garrigou P,Mayol JF,Hérodin F

    更新日期:2008-03-01 00:00:00

  • Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

    abstract::Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.066217

    authors: Seiki Y,Sasaki Y,Hosokawa K,Saito C,Sugimori N,Yamazaki H,Takami A,Nakao S

    更新日期:2013-06-01 00:00:00

  • Simultaneous occurrence of B-cell chronic lymphocytic leukemia and chronic myeloid leukemia with further evolution to lymphoid blast crisis.

    abstract::The coexistence of chronic myeloid leukemia (CML) and B-cell chronic lymphocytic leukemia (CLL) in the same patient is rare. A 71-year-old woman developed a B-lineage lymphoid blast crisis at 18 months after diagnosis of Ph-positive CML. At this time, a lymphoid cell population with morphologic and immunophenotypic fe...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Esteve J,Cervantes F,Rives S,Rozman M,Zarco MA,Montserrat E

    更新日期:1997-09-01 00:00:00

  • Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.

    abstract:BACKGROUND AND OBJECTIVES:We investigated whether cytogenetic findings (CG) on day 21 (D21) of the first course of chemotherapy predicted subsequent outcome in patients who presented with CG abnormalities. DESIGN AND METHODS:D21 CG analysis was performed in 197 patients. RESULTS:Nineteen percent of the patients had e...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Konopleva M,Cheng SC,Cortes JE,Hayes KJ,Pierce SA,Andreeff M,Giles FJ,O'Brien S,Kantarjian HM,Estey EH

    更新日期:2003-07-01 00:00:00

  • Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.

    abstract::Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy. For patients with relapsed/refractory multiple myeloma, we developed a treatment schema of metronomically scheduled drug therapy. We identified 186 patients who had been treated with metronomic therapy between March 2004 and...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.085183

    authors: Papanikolaou X,Szymonifka J,Rosenthal A,Heuck CJ,Mitchell A,Johann D Jr,Keller J,Waheed S,Usmani SZ,Van Rhee F,Bailey C,Petty N,Hoering A,Crowley J,Barlogie B

    更新日期:2013-07-01 00:00:00

  • Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

    abstract:BACKGROUND:Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant protein that stimulates activated protein C and tissue factor pathway inhibitor. Hereditary type I protein S deficiency (low total and low free protein S) is a well-established risk factor for venous thrombosis, whereas t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.021923

    authors: Castoldi E,Maurissen LF,Tormene D,Spiezia L,Gavasso S,Radu C,Hackeng TM,Rosing J,Simioni P

    更新日期:2010-09-01 00:00:00

  • Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.

    abstract:BACKGROUND:Vgamma9Vdelta2 T lymphocytes are regarded as promising mediators of cancer immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly within those of hematopoietic origin. However, Vgamma9Vdelta2 T-cell based lymphoma clinical trials have suffered from the lack of biomarkers ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.020602

    authors: Gomes AQ,Correia DV,Grosso AR,Lança T,Ferreira C,Lacerda JF,Barata JT,Silva MG,Silva-Santos B

    更新日期:2010-08-01 00:00:00